文献速递膀胱癌与上尿路尿路上皮癌

局部晚期膀胱癌根治性膀胱切除术后延迟启动辅助化疗的生存获益仍然存在

Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer.
PubMed 文献 · Urology · 2019-06-11

该回顾性队列研究利用2006至2013年美国国家癌症数据库,纳入根治性膀胱切除术后病理为局部晚期(pT3-T4和/或pN+)且未接受新辅助化疗的肌层浸润性膀胱癌患者,比较不同时间启动多药辅助化疗与未化疗者的总生存。结果显示,术后31-60天、61-90天和91-180天启动辅助化疗均降低死亡风险,提示即使延迟启动仍可获益。

要点

  • 术后31-60天启动辅助化疗较未化疗降低死亡风险(HR 0.60,95%CI 0.52-0.69,P<.001)。
  • 术后61-90天启动辅助化疗较未化疗降低死亡风险(HR 0.62,95%CI 0.53-0.74,P<.001)。
  • 术后91-180天启动辅助化疗较未化疗仍降低死亡风险(HR 0.69,95%CI 0.55-0.87,P=.002)。

核心结论

  • 对于未接受新辅助化疗的高危患者,根治性膀胱切除术后6个月内启动辅助化疗均提供生存获益。
  • 需要延迟启动辅助化疗的患者仍可从治疗中获益。

研究设计与样本

  • 回顾性队列研究,利用2006至2013年美国国家癌症数据库。
  • 纳入接受根治性膀胱切除术、病理为局部晚期(pT3-T4和/或pN+)的肌层浸润性膀胱癌初治患者。
  • 患者术后30至180天内未接受化疗或接受多药辅助化疗。
  • 采用多变量Cox回归评估辅助化疗启动时间与总生存的差异。

主要发现

  • 共识别3590例患者:2581例未接受化疗,1009例接受多药辅助化疗。
  • 辅助化疗于术后31-60天启动538例,61-90天启动321例,91-180天启动150例。
  • 与未接受化疗者相比,术后31-60天启动辅助化疗降低死亡风险(HR 0.60,95%CI 0.52-0.69,P<.001)。
  • 与未接受化疗者相比,术后61-90天启动辅助化疗降低死亡风险(HR 0.62,95%CI 0.53-0.74,P<.001)。
  • 与未接受化疗者相比,术后91-180天启动辅助化疗降低死亡风险(HR 0.69,95%CI 0.55-0.87,P=.002)。

临床怎么用

  • 对于根治性膀胱切除术后病理为局部晚期且未接受新辅助化疗的患者,术后6个月内启动多药辅助化疗可考虑用于改善生存。
  • 需要延迟启动辅助化疗的患者仍可考虑接受治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if delaying the initiation of adjuvant chemotherapy following radical cystectomy for locally advanced bladder cancer worsens overall survival. METHODS: This is a retrospective cohort study utilizing the National Cancer Database from 2006 to 2013. We included treatment-naïve patients who underwent radical cystectomy for muscle-invasive bladder cancer found to have locally advanced disease (pT3-T4 and/or pN+). Patients received no chemotherapy or multiagent adjuvant chemotherapy between 30 and 180 days following surgery. We used a multivariable Cox Regression to assess for differences in overall survival according to when patients initiated adjuvant chemotherapy. RESULTS: We identified 3590 patients: 2581 received no chemotherapy and 1009 received multiagent adjuvant chemotherapy. Adjuvant chemotherapy began 31-60 days postsurgery in 538 patients, 61-90 days in 321 patients, and 91-180 days in 150 patients. Relative to patients who did not receive chemotherapy, adjuvant chemotherapy decreased mortality when started 31-60 days (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.52-0.69; P <.001), 61-90 days (HR, 0.62; 95% CI, 0.53-0.74; P <.001), and 91-180 days following radical cystectomy (HR, 0.69; 95% CI, 0.55-0.87; P = .002). CONCLUSION: Adjuvant chemotherapy offers a survival benefit when started up to 6 months after radical cystectomy in patients with high-risk disease who did not receive neoadjuvant chemotherapy. Patients who require delayed initiation of adjuvant chemotherapy can still benefit from treatment.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Corbett CJ, Xia L, Mamtani R, et al. Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. Urology. 2019. PMID: 31199968. doi:10.1016/j.urology.2019.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。